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Background: The only available score to assess the risk for fatal bleeding in patients with venous thromboem-
bolism (VTE) has not been validated yet.
Methods:We used the RIETE database to validate the risk-score for fatal bleeding within the ﬁrst 3 months of
anticoagulation in a new cohort of patients recruited after the end of the former study. Accuracy was mea-
sured using the ROC curve analysis.
Results: As of December 2011, 39,284 patients were recruited in RIETE. Of these, 15,206 had not been included in
the former study, and were considered to validate the score.Within the ﬁrst 3 months of anticoagulation, 52 pa-
tients (0.34%; 95% CI: 0.27-0.45) died of bleeding. Patients with a risk score of b1.5 points (64.1% of the cohort)
had a 0.10% rate of fatal bleeding, thosewith a score of 1.5-4.0 (33.6%) a rate of 0.72%, and thosewith a score of N4
points had a rate of 1.44%. The c-statistic for fatal bleeding was 0.775 (95% CI 0.720-0.830). The score performed
better for predicting gastrointestinal (c-statistic, 0.869; 95% CI: 0.810-0.928) than intracranial (c-statistic, 0.687;
95% CI: 0.568-0.806) fatal bleeding. The score value with highest combined sensitivity and speciﬁcity was 1.75.
The risk for fatal bleeding was signiﬁcantly increased (odds ratio: 7.6; 95% CI 3.7-16.2) above this cut-off value.
Conclusions: The accuracy of the score in this validation cohort was similar to the accuracy found in the index
study. Interestingly, it performed better for predicting gastrointestinal than intracranial fatal bleeding.© 2013 The Authors. Published by Elsevier Ltd. All rights reserved.Introduction
Venous thromboembolism (VTE) is a commonly diagnosed condi-
tionwith signiﬁcantmorbidity andmortality [1]. Current guidelines rec-
ommend patients with VTE to be initially treated with low-molecular-
weight heparin (LMWH), unfractionated heparin or fondaparinux,
followed by long-term anticoagulation, which is usually accomplishedTE, Registro Informatizado de
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blished by Elsevier Ltd. All rights rewith vitamin K antagonists (VKA) [2,3]. Recommendations for long-
term therapy are based on randomized clinical trials [2–10] that
assessed relevant outcomes like VTE recurrences and major bleeding
rates, because most trials were underpowered to assess fatal VTE
or fatal bleeding events. Furthermore, a number of patients are often ex-
cluded from randomized trials of anticoagulation because of co-morbid
conditions, short life expectancy, pregnancy or contraindications to
therapy, which means that treatment regimens based on the results
from randomized clinical trialsmight not be generalisable to all patients
with VTE.
When weighing the risks and beneﬁts of anticoagulation in an in-
dividual patient, in addition to considering the absolute risk of VTE
recurrences and major bleeding, the mortality associated with each
of these outcomes should be considered. While a number of prognos-
tic models have the potential to predict the risk for major bleeding
[11–13], little has been done to identify patients at increased risk to
die of bleeding during the course of anticoagulation. In a previous
study using data from the RIETE registry [14], we identiﬁed 9 clinicalserved.
Table 1
RIETE score for fatal bleeding in patients receiving anticoagulation
for acute venous thromboembolism [14].
Points
Age N75 years 1
Metastatic cancer 2
Immobility ≥4 days⁎ 1
Recent major bleeding# 1.5
Abnormal prothrombin time 1
CrCl b 30 ml/min 1
Platelet Count b100 × 109/L 1
Anemia† 1
Distal DVT -1
⁎ deﬁned as non-surgical patients who were conﬁned to bed
with bathroom privileges for ≥4 days in the 2-months prior to VTE
diagnosis.
# major bleeding less than 30 days before VTE diagnosis.
† deﬁned as hemoglobin b13 g/dL in men or b12 g/dL in women.
Table 2
Clinical characteristics of patients with and without subsequent fatal bleeding.
Fatal bleeding No fatal bleeding p value
Patients, N 52 15,154
Clinical characteristics,
Gender (males) 26 (50%) 7,367 (49%) 0.89
Age N75 years 24 (46%) 5,260 (35%) 0.11
Body weight b70 kg 30 (58%) 5,544 (37%) 0.002
Underlying diseases,
Chronic lung disease 7 (14%) 1,759 (12%) 0.66
Chronic heart disease 5 (9.6%) 1,079 (7.1%) 0.42
Recent major bleeding 2 (3.8%) 316 (2.1%) 0.30
Risk factors for VTE,
Recent immobility ≥ 4 days 15 (29%) 3,470 (23%) 0.32
Recent surgery 5 (9.6%) 1,680 (11%) 1.00
Cancer 29 (56%) 3,439 (23%) b0.001
Metastatic cancer 20 (39%) 1,405 (9.3%) b0.001
Prior VTE 3 (5.8%) 2,341 (15%) 0.054
Baseline blood tests,
Anemia 32 (62%) 5,232 (55%) b0.001
Platelet count b100 × 109/L 6 (12%) 374 (2.5%) 0.002
Abnormal prothrombin time 9 (17%) 1,114 (7.4%) 0.013
CrCl levels b30 ml/min 10 (19%) 1,119 (7.4%) 0.004
VTE characteristics,
Symptomatic PE 32 (62%) 7,782 (51%) 0.17
Bilateral DVT 6 (12%) 578 (3.8%) 0.01
Distal DVT 3 (5.8%) 1,728 (11%) 0.27
Initial therapy
LMWH 45 (88%) 13,550 (89%) 0.50
Unfractionated heparin 3 (5.9%) 887 (5.9%) 1.00
Thrombolytics 3 (5.9%) 158 (1.0%) 0.02
Vena cava ﬁlter 1 (1.9%) 372 (2.5%) 1.00
Long-term therapy
LMWH 17 (33%) 3,994 (26%) 0.34
Vitamin K antagonists 13 (25%) 10,358 (68%) b0.001
Abbreviations: VTE, venous thromboembolism; CrCl, creatinine clearance; PE, pulmo-
nary embolism; DVT, deep vein thrombosis; LMWH, low-molecular-weight heparin.
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ated with an increased risk for fatal bleeding within the ﬁrst
3 months of anticoagulation, and built a prognostic score to identify
patients at low-, moderate- or high risk. In the current study, we
tried to validate this score using a new sample of patients recruited
in RIETE after the end of the former study.
Patients and Methods
TheRIETE (Registro Informatizado de Enfermedad TromboEmbólica)
Registry is an ongoing, multicenter, international (Spain, Italy, France,
Israel, Portugal, Germany, Switzerland, Czech Republic, Macedonia,
United States, Brazil and Ecuador), observational registry of consecutive
patients with symptomatic, objectively conﬁrmed, acute VTE [15–17].
Consecutive patients with symptomatic, acute deep vein thrombo-
sis (DVT) or pulmonary embolism (PE), conﬁrmed by objective tests
(contrast venography or ultrasonography for suspected DVT; pulmo-
nary angiography, lung scintigraphy, or helical computed tomography
scan for suspected PE), were enrolled in RIETE. Patients were excluded
if they did not receive any anticoagulant therapy or were currently
participating in a therapeutic clinical trial with a blinded therapy. All
patients provided consent to their participation in the registry, in
accordance with local Ethics Committee requirements.
In the RIETE registry, participating physicians ensured that eligible
patients were consecutively enrolled. Data were recorded on to a
computer-based case report form at each participating hospital and sub-
mitted to a centralized coordinating center through a secure website.
The study coordinating center assigned patients with a unique identiﬁ-
cation number to maintain patient conﬁdentiality and was responsible
for all datamanagement. Data qualitywas regularlymonitored electron-
ically, including checks to detect inconsistencies or errors, which were
resolved by the local coordinators. Data quality was also monitored by
periodic visits to participating hospitals by contract research organiza-
tions that compared medical records with the submitted data, and
made sure that consecutive patients had been recruited into RIETE.
Study Outcomes
Fatal bleedingwas deﬁned as any death occurring within 7 days of a
major bleeding episode, in the absence of an alternative cause of death.
Major bleeding was deﬁned as an overt bleed that required a transfu-
sion of 2 or more units of blood, was retroperitoneal, spinal or intracra-
nial, or was fatal. The causes of death were assigned by their attending
physicians.
Baseline Variables and Score
The baseline variables registered in RIETE have been described
elsewhere [15–17]. Data were recorded when the qualifying episode
of VTE was diagnosed. The 9 independent variables associated with
an increased risk for fatal bleeding and the points assigned to each
variable are presented in Table 1. The patient’s score is the sum of
the points assigned to each variable.
Treatment and Follow-up
Patientsweremanaged according to the clinical practice of each par-
ticipating hospital (i.e., there was no standardization of treatment). The
type and dose of anticoagulant therapy, as was the insertion of an infe-
rior vena cava ﬁlter, were recorded. After discharge, all patients were
followed-up for up to 3 months in the outpatient clinic. During each
visit, any signs or symptoms suggesting either DVT or PE recurrences
or bleeding complications were noted. Most outcomes were classiﬁed
as reported by the clinical centers. However, if the staff at the coordinat-
ing center was in disagreement on how to classify a reported outcome,
that event was reviewed by a central adjudicating committee (less than10% of events). Patients who hadmajor bleeding or recurrent VTEwith-
in 3 months of enrollment remained under surveillance until 3 months
of follow-up was completed.
Statistical Analysis
Student’s t test and the Mann-Whitney test were used to compare
continuous variables. Qualitative variables were compared by the
Fisher exact test, and the odds ratio and 95% conﬁdence intervals
were calculated. Survival curves were constructed according to the
Kaplan-Meyer method. The cut-off points for risk categories of fatal
bleeding have been previously reported [14]. Receiver Operating
Characteristics (ROC) curve analysis and the c-statistic was used to
assess the accuracy of the score and to identify the score values
Table 3
Sites of major and fatal bleeding.
Fatal bleeding
(n = 52)
Non-fatal major
bleeding (n = 198)
Major bleeding
(n = 250)
Gastrointestinal 19 (36.5%) 62 (31.1%) 81 (32.4%)
Intracranial 14 (26.9%) 18 (9.1%) 32 (12.8%)
Genitourinary 2 (3.8%) 26 (13.1%) 28 (11.2%)
Hematoma 11 (21.2%) 65 (32.8%) 76 (30.4%)
Other 6 (11.5%) 27 (13.6%) 33 (13.2%)
Table 5
C-statistic according to site of bleeding.
c-statisic 95% CI Standard error n
Fatal bleeding,
All sites 0.775 0.720–0.830 0.028 52
Extracranial 0.807 0.750–0.864 0.029 38
Intracranial 0.687 0.568–0.806 0.061 14
Gastrointestinal 0.869 0.810–0.928 0.030 19
Muscular/Hematoma 0.737 0.630–0.843 0.054 11
All-cause death 0.839 0.828–0.850 0.06 1181
Major bleeding 0.719 0.689–0.749 0.015 250
Abbreviations: CI, conﬁdence intervals.
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(version 15, SPSS Inc., Chicago, Illinois) was used for the statistical
management of the data, and a two-sided p b0.05 was considered
to be statistically signiﬁcant.Results
As of December 2011, 39,284 patients were recruited into the
RIETE registry. Of these, 15,206 had not been included in the former
study, and were considered for validating the score. In all, 7,814 pa-
tients (51%) initially presented with PE (with or without concomitant
DVT) and 7,392 with DVT alone. Their clinical characteristics are
shown in Table 2. Most patients (89%) received initial therapy with
LMWH, 5.9% received unfractionated heparin, 1.1% thrombolytic ther-
apy, and 2.5% an inferior vena cava ﬁlter. For long-term therapy,
10,371 patients (68%) received VKA and 4,011 (26%) had LMWH.
Within the ﬁrst 3 months of anticoagulation, 250 patients (1.64%;
95% CI: 1.45-1.86) had major bleeding complications and 52 (0.34%;
95% CI: 0.27-0.45) died of bleeding. Patients subsequently dying of
bleedingmore likely had cancer, andmore likely presentedwith anemia,
platelet count b100 × 109/L, abnormal prothrombin time or renal insuf-
ﬁciency compared with those with no fatal bleeding (Table 2). Themost
frequent site of fatal bleeding (19 of 52 fatal bleeds, 36.5%)was gastroin-
testinal (GI), and the highest mortality occurred after intracranial bleed-
ing (14 of 32 major bleeds, 43.7%), as shown in Table 3. One in every 5
fatal bleeding events occurred after a second episode of major bleeding
in the same location.
The rate of fatal bleeding increased in parallel to the patient’s risk
score (Table 4). Patients with a risk score of b1.5 points (64.1% of the
whole series) had a 0.10% rate of fatal bleeding (10 in 9,748 patients),
those with a risk score of 1.5-4.0 (33.6% of patients) a rate of 0.72%
(37 in 5,111 patients), and those with a score of N4 had a rate of 1.44%
(5 in 347 patients). The c-statistic for fatal bleedingwith the continuous
score was 0.775 (95% CI: 0.720-0.830). Performance was highest for GI
bleeding (0.869; 95% CI: 0.810-0.928) and lowest for intracranial bleed-
ing (0.687; 95% CI: 0.568-0.806), as shown in Table 5. Accuracy of theTable 4
Risk categories (low-, intermediate-, high-) of the patients according to score, and cor-
responding rates of fatal bleeding.
Points All patients
(N = 15,206)
Fatal bleeding
(N = 52)
Fatal bleeding rate
per risk category
-1 667 (4.4%) 0 0
0-0.99 4,646 (30.6%) 2 (3.8%) 0.04%
1-1.99 4,465 (29.4%) 8 (15.4%) 0.18%
2-2.99 2,774 (18.2%) 15 (28.9%) 0.54%
3-3.99 1,664 (10.9%) 13 (25%) 0.78%
4-4.99 704 (4.6%) 11 (21.2%) 1.56%
5-5.99 229 (1.5%) 3 (5.8%) 1.31%
6-6.99 49 (0.3%) 0 0
7-7.99 7 (0.05%) 0 0
8-8.5 1 (0.007%) 0 0
Risk category,
Low (b1.5) 9,748 (64.1%) 10 (19.2%) 0.10%
Moderate (1.5-4) 5,111 (33.6%) 37 (71.2%) 0.72%
High risk (N4) 347 (2.28%) 5 (9.6%) 1.44%high risk (N4 points) score for GI, extracranial or intracranial fatal bleed-
ing appears in Table 6.
The score value with highest combined sensitivity and speciﬁcity
was 1.75 (Fig. 1). Risk for fatal bleeding was signiﬁcantly increased
above this cut-off point (odds ratio [OR]: 7.6; 95% CI: 3.7-16.2), and
most fatal bleeding events (42 of 52, 80.1%) occurred in patients ex-
ceeding it. The accuracy of the cut-off score (1.75 points) for GI, extra-
cranial or intracranial fatal bleeding appears in Table 6. The negative
predictive value for any fatal bleeding is 99.9% and the negative like-
lihood ratios for GI and extracranial fatal bleeds is 0.08 and 0.20, re-
spectively (Table 6). The cumulative rate of fatal bleeding using the
cut-off point appears in Fig. 2. The majority of patients (18 of 19,
94.7%) dying after GI bleeding (OR: 32.5; 95% CI: 4.6-115.8) and
most patients (33 of 38, 86.8%) dying after extracranial bleeding
(OR: 12.0; 95% CI 4.5-34.8) had score values above the cut-off point.
Discussion
Our ﬁndings, obtained from a large series of consecutive patients re-
ceiving anticoagulation for acute VTE, conﬁrm the validity of the score.
About two-thirds of patients were considered to be at low-risk accord-
ing to the risk scorewith a 3-month rate of fatal bleeding of 0.10%, about
one-third were considered to be at moderate-risk and had a rate of
0.72%, and about 2% were considered to be at high-risk with a rate of
1.44%. Interestingly, the best cut-off point (score, 1.75, only slightly
over the upper limit of the low risk category) correctly identiﬁed the
subgroup of patients with 7 to 30-fold higher risk for fatal bleeding
(depending on sites of bleeding). In patients at high risk for fatal bleed-
ing it may be wise to administer anticoagulants at a lower intensity (or
even to withhold anticoagulation and insert a vena cava ﬁlter), alter
other medications, or monitor therapy and signs of bleeding more
closely, as early detection of major bleeding might reduce mortality.
On the other hand, our score also identiﬁed two in every 3 patients
(64.1%) with a very low (0.10%) rate of fatal bleeding, which is also
reassuring. Only 10 of 52 patients with fatal bleeds scored less thanTable 6
Accuracy of the high-risk (N4 points) and the cut-off (1.75 points) scores for predicting
fatal bleeding.
Any Gastrointestinal Extracranial Intracranial
High-risk score (N4 points),
Sensitivity 9.6% 15.8% 10.5% 7.1%
Speciﬁcity 97.8% 97.7% 97.7% 97.7%
Positive predictive value 1.4% 0.9% 1.2% 0.35%
Negative predictive value 99.7% 99.9% 99.8% 99.9%
Positive likelihood ratio 4.27 6.97 4.65 3.14
Negative likelihood ratio 0.92 0.86 0.92 0.95
Cut-off score (1.75 points),
Sensitivity 80.8% 94.7% 86.8% 64.3%
Speciﬁcity 64.5% 64.4% 64.4% 64.3%
Positive predictive value 0.8% 0.3% 0.6% 0.2%
Negative predictive value 99.9% 100% 99.9% 99.9%
Positive likelihood ratio 2.27 2.66 2.44 1.80
Negative likelihood ratio 0.30 0.08 0.20 0.56
Fig. 1. Receiver operating characteristics curve for any fatal bleeding according to the
continuous score (c-statistic 0.775). The black circle represents the position of the
cut-off point (score, 1.75) with the highest combined sensitivity (81%) and speciﬁcity
(64.5%).
178 J.A. Nieto et al. / Thrombosis Research 132 (2013) 175–1791.75 (false negative), what explains the roughly 100% negative predic-
tive value. According to the c-statistic, our score performance was
comparable to (or even better than) other well known scores used in
clinical practice [18,19] to predict major bleeding in different patient
populations.
Our score had statistically signiﬁcant value, but should be consid-
ered only a ﬁrst step for better understanding the effect of combined
risk factors. Its positive predictive value in patients at high-risk is low
(1.4%), and its positive likelihood ratio (4.27) is close to the level for
moderate performance [20]. The c-statistic reﬂects the ability of the pre-
diction model to discriminate the outcome (a value of 1.0 reﬂects per-
fect discrimination; 0.5 is no better than chance alone). Thus, it seems
to be of value for decision making in clinical practice. Moreover, our
score performed better in predicting fatal GI bleeding according to theFig. 2. Cumulative incidence of fatal bleeding according to a cut-off score of 1.75.c-statistic (0.869) and the positive likelihood ratio (6.97), and worse
in predicting fatal intracranial bleeding. Thus, our ﬁndings suggest
that GI and intracranial bleeding may have different risk factors, and
may deserve a different approach. Speciﬁc risk-factors for intracranial
bleeding (i.e., arterial hypertension or previous intracranial bleeding)
are not adequately weighed in our score to predict this outcome. There-
fore, in order tomore precisely assess the risk for fatal bleeding, itwould
be wise to use speciﬁc scores for different sites of bleeding.
The present study has some potential limitations that should be
addressed. First, RIETE does not have a standardized protocol to treat
their patients. Thus, physicians treat VTE and bleeding episodes accord-
ing to local clinical practice. Second, we do not have enough data to as-
sess the inﬂuence of elements that may change during the course of the
disease, like the INR control, the use of concomitant medications or the
presence of intercurrent diseases. Third, the scorewas validated in a fur-
ther RIETE cohort, which is not a completely independent patient sam-
ple, and therefore, unrecognized ﬂaws that could be present in the
previous studymay be reproduced in this. However, while only Spanish
patients were included in the index study, in the current cohort sample
one in every 3 patients was coming from other countries. Finally,
the rate of fatal bleeding in the former study was 0.55% (95%
CI: 0.47-0.65)14 and in the current study 0.34% (95% CI: 0.27-0.45). A
plausible explanation for the lower rate of fatal bleeding in the current
study may be the lower proportion of patients with independent pre-
dictors for fatal bleeding, such as age over 75 years (46% vs. 63%), recent
immobility (29% vs. 47%) or severe renal insufﬁciency (19% vs. 27%)
compared to the former series [14]. In contrast, the use of thrombolytics
wasmore frequent in patients with fatal bleeding in this study (3 cases,
5.9%) compared to the original (2 cases, 1.5%). This is a relevant differ-
ence between the derivation and the validation cohorts that may
explain part of the variation in the score accuracy.
In summary, the current study validated the accuracy of the fatal
bleeding score, and reveals the greatest performance for extracranial
bleeds. This score still needs to be validated in an independent patient
sample, but it might represent a valid tool for tailoring anticoagulation
of VTE patients at high-risk for fatal bleeding.
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